GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (OTCPK:TCBPY) » Definitions » Notes Receivable

TCBPY (TC BioPharm (Holdings)) Notes Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Notes Receivable?

TC BioPharm (Holdings)'s Notes Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.


TC BioPharm (Holdings) Notes Receivable Historical Data

The historical data trend for TC BioPharm (Holdings)'s Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Notes Receivable Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

TC BioPharm (Holdings) Quarterly Data
Dec19 Dec20 Sep21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TC BioPharm (Holdings) Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


TC BioPharm (Holdings) Notes Receivable Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


TC BioPharm (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
Executives
Renaissance Capital Partners Ltd 10 percent owner 42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD